The Second Clinical Medical College, Guangzhou University of Chinese Medicine, Guangzhou, 510405, China.
Department of Nephrology, Guangdong Provincial Hospital of Chinese Medicine, Guangzhou, 510120, China.
Adv Rheumatol. 2023 Jul 18;63(1):32. doi: 10.1186/s42358-023-00310-6.
Gout is a common inflammatory arthritis caused by increased serum uric acid levels. Untreated or insufficiently treated gout can lead to deposition of monosodium urate crystals in joints, cartilage, and kidneys. Although Tongfengding capsules, a Chinese patent medicine, have long been used to treat gout, their effects and safety have not been reviewed systematically. This study evaluated its efficacy and safety for gout in adults.
Randomized controlled trials involving Tongfengding capsule for gout in adults were searched from PubMed, EMBASE, Cochrane Central Register of Controlled Trials, CBM, CNKI, and VIP databases, and analyzed using the Cochrane Handbook criteria. The primary outcome measures were the total effective rate. The secondary outcome measures including the blood uric acid (BUA), 24-h urinary total protein (24-h UTP), blood urea nitrogen (BUN), interleukin (IL)-6, IL-8, tumor necrosis factor-alpha (TNF-α) and adverse effects. The risk of bias was evaluated in all included studies. RevMan ver. 5.3.5 and GRADE profiler was used for data analysis and assessing the quality of evidence, respectively.
Six studies (n = 607 Chinese participants) were included. Tongfengding capsules plus conventional treatment significantly increased the total effective rate (RR 1.21, 95% CI 1.11-1.33), while reducing the BUA (MD - 66.05 µmol/L, 95% CI - 81.26 to - 50.84), 24-h UTP (MD - 0.83 g/24 h, 95% CI - 0.96 to - 0.70), BUN (MD - 0.90 mmol/L, 95% CI - 1.60 to - 0.20), IL-6 (MD - 6.99 ng/L, 95% CI - 13.22 to - 0.75), IL-8 (MD - 12.17 ng/L, 95% CI - 18.07 to - 6.27), TNF-α (MD - 8.50 ng/L, 95% CI - 15.50 to - 1.51), and adverse effects (RR 0.21, 95% CI 0.04-0.95).
Tongfengding capsules plus conventional treatment is safe and beneficial for adults with gout compared with conventional treatment.
痛风是一种常见的炎症性关节炎，由血清尿酸水平升高引起。未经治疗或治疗不充分的痛风会导致单钠尿酸盐晶体在关节、软骨和肾脏中沉积。虽然痛风定胶囊是一种中药已有很长时间用于治疗痛风，但尚未系统评估其在成人中的疗效和安全性。本研究评估了痛风定胶囊治疗成人痛风的疗效和安全性。
从 PubMed、EMBASE、Cochrane 中心对照试验注册库、CBM、CNKI 和 VIP 数据库中检索到涉及痛风定胶囊治疗成人痛风的随机对照试验，并按照 Cochrane 手册标准进行分析。主要结局指标为总有效率。次要结局指标包括血尿酸（BUA）、24 小时尿总蛋白（24-h UTP）、血尿素氮（BUN）、白细胞介素（IL）-6、IL-8、肿瘤坏死因子-α（TNF-α）和不良反应。所有纳入的研究均评估了偏倚风险。RevMan ver. 5.3.5 和 GRADE profiler 分别用于数据分析和评估证据质量。
纳入了 6 项研究（n=607 名中国参与者）。痛风定胶囊联合常规治疗显著提高了总有效率（RR 1.21，95%CI 1.11-1.33），同时降低了 BUA（MD -66.05 µmol/L，95%CI -81.26 至 -50.84）、24-h UTP（MD -0.83 g/24 h，95%CI -0.96 至 -0.70）、BUN（MD -0.90 mmol/L，95%CI -1.60 至 -0.20）、IL-6（MD -6.99 ng/L，95%CI -13.22 至 -0.75）、IL-8（MD -12.17 ng/L，95%CI -18.07 至 -6.27）、TNF-α（MD -8.50 ng/L，95%CI -15.50 至 -1.51）和不良反应（RR 0.21，95%CI 0.04-0.95）。
与常规治疗相比，痛风定胶囊联合常规治疗对成人痛风安全且有益。
